derazantinib   Click here for help

GtoPdb Ligand ID: 9785

Synonyms: ARQ-087 | ARQ087
Compound class: Synthetic organic
Comment: Derazantinib (ARQ087) is an orally bioavailable, non-selective FGFR inhibitor being investigated for antineoplastic activity. Preclinical activity is reported by Hall et al. (2016) [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 59.07
Molecular weight 468.23
XLogP 4.73
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COCCNCCc1cccc(c1)Nc1ncc2c(n1)c1ccccc1C(C2)c1ccccc1F
Isomeric SMILES COCCNCCc1cccc(c1)Nc1ncc2c(n1)c1ccccc1[C@@H](C2)c1ccccc1F
InChI InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
Bioactivity Comments
Derazantinib exhibits anti-proliferative activity vs. cell lines driven by FGFR dysregulation and is active in vivo, in xenograft tumour models with FGFR gene amplifications and fusions.
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
fibroblast growth factor receptor 2 Hs Inhibitor Inhibition 8.7 pIC50 - 1
pIC50 8.7 (IC50 1.8x10-9 M) [1]
fibroblast growth factor receptor 1 Hs Inhibitor Inhibition 8.4 pIC50 - 1
pIC50 8.4 (IC50 4.5x10-9 M) [1]
fibroblast growth factor receptor 3 Hs Inhibitor Inhibition 8.4 pIC50 - 1
pIC50 8.4 (IC50 4.5x10-9 M) [1]